Journeys: understanding access, affordability and disruptions to cancer care in India [0.03%]
癌症诊疗之路——印度癌症医疗服务的可及性、经济性和干扰因素分析报告
Soumitra Shankar Datta,Soumita Ghose,Manisha Ghosh et al.
Soumitra Shankar Datta et al.
Background: Much of the global cancer burden is in low- and middle-income countries (LMICs). Along with the high incidence of cancer, most LMICs have unevenly distributed health care resources. This study is a qualitative...
Gordon McVie: his legacy as a blueprint for cancer advocates as we strive towards the 2030 global health and sustainable development goals [0.03%]
戈登·麦克维:他作为癌症倡导者的遗泽以及我们努力实现2030年全球健康和可持续发展目标的过程中的蓝图效应
Gabriella Pravettoni,Marianna Masiero,Christine Mugo-Sitati et al.
Gabriella Pravettoni et al.
Cancer prevention and control services worldwide must actively rebuild and contribute to improved health systems resilience alongside and beyond the COVID-19 (SARS-CoV-2 coronavirus disease) pandemic, especially in low- and middle-income co...
Ian F Tannock
Ian F Tannock
Gordon McVie campaigned throughout his career for merging scientific and clinical expertise and for investigating the underlying pharmacokinetics and pharmacodynamics in clinical trials. This need remains highly relevant today when most can...
Contingency planning for cancer care in low- and middle-income countries during the COVID-19 pandemic: a rapid assessment for future disaster resilience [0.03%]
新冠肺炎疫情期间低收入和中等收入国家癌症护理的应急规划:对未来灾难应对能力的快速评估
Soo-Peng Teoh,Yee-Yin Hoo,Raul Murillo et al.
Soo-Peng Teoh et al.
Background: Many countries appear to be ill-prepared in their emergency responses towards the Corona Virus Disease 2019 (COVID-19) pandemic, particularly in managing chronic diseases such as cancer. We aimed to gain insig...
Predictors of pathologic complete response to neoadjuvant treatment in HER2-overexpressing breast cancer: a retrospective analysis using real-world data [0.03%]
HER2阳性乳腺癌新辅助治疗病理完全缓解的预测因素:真实世界数据分析回顾性研究
Isabel Saffie Vega,Jorge Sapunar Zenteno,Felipe Buscaglia Fernandez et al.
Isabel Saffie Vega et al.
The human epidermal growth factor receptor 2 (ERBB2, HER2 or HER2/neu) is a transmembrane tyrosine kinase receptor that is overexpressed in approximately 20% of breast cancers. The use of the anti-HER2 monoclonal antibodies Pertuzumab and T...
Case Reports
Ecancermedicalscience. 2022 Jan 6:16:1338. DOI:10.3332/ecancer.2022.1338 2022
Yan Fei Gu,Frank P Lin,Richard J Epstein
Yan Fei Gu
Population aging is causing a demographic redistribution with implications for the future of healthcare. How will this affect oncology? First, there will be an overall rise in cancer affecting older adults, even though age-specific cancer i...
PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer? [0.03%]
PARP抑制剂作为放疗增敏剂:前列腺癌的未来前景展望?
Martin Angel,Martin Zarba,Juan Pablo Sade
Martin Angel
Poly (ADP-ribose) polymerase (PARP) inhibitors (iPARPs) have shown efficacy in homologous recombination (HR) deficiency patients with advanced castration resistant prostate cancer and have shown a radiosensitizing effect in preclinical and ...
Pathologist's perspectives on reporting of tumour budding in colorectal cancer [0.03%]
病理学家视角下的结直肠癌肿瘤芽生的报告问题
Paromita Roya,Lateef Zameer,Debdeep Dey et al.
Paromita Roya et al.
Purpose: Tumour budding (TB) is an important adverse prognostic factor in colon cancer, which can also guide adjuvant treatment in stage II colorectal carcinoma. The International Tumor Budding Consensus Conference (ITBCC...
Life expectancy and cancer survival in Oncosalud: outcomes over a 15-year period in a Peruvian private institution [0.03%]
秘鲁一家私营机构Oncosalud 15年预期寿命和癌症生存期分布
Christian Colonio,Luciana Lecman,Joseph A Pinto et al.
Christian Colonio et al.
Background: There is a large gap in the data on cancer outcomes in Latin America, making it difficult to establish adequate cancer control policies in the region. The aim of our study was to describe the survival, life ex...
Not so 'rare'-an example of malignant melanoma in India: report from a tertiary cancer centre [0.03%]
印度三级肿瘤中心恶性黑色素瘤病例报告:并非“罕见”
Bivas Biswas,Gautam Biswas,Sandip Ganguly et al.
Bivas Biswas et al.
Purpose: Malignant melanoma (MM) is rare in India. Indian data on demography and treatment outcome on advanced MM is very limited in the literature. Mater...